Literature DB >> 12829610

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

Katayoun Rezvani1, Matthias Grube, Jason M Brenchley, Giuseppe Sconocchia, Hiroshi Fujiwara, David A Price, Emma Gostick, Ko Yamada, Jan Melenhorst, Richard Childs, Nancy Hensel, Daniel C Douek, A John Barrett.   

Abstract

Antigens implicated in the graft-versus-leukemia (GVL) effect in chronic myeloid leukemia (CML) include WT1, PR1, and BCR-ABL. To detect very low frequencies of these antigen-specific CD8+ T cells, we used quantitative polymerase chain reaction (qPCR) to measure interferon-gamma (IFN-gamma) mRNA production by peptide-pulsed CD8+ T cells from HLA-A*0201+ healthy volunteers and from patients with CML before and after allogeneic stem cell transplantation (SCT). Parallel assays using cytomegalovirus (CMV) pp65 tetramers demonstrated the IFN-gamma copy number to be linearly related to the frequency of tetramer-binding T cells, sensitive to frequencies of 1 responding CD8+ T cell/100 000 CD8+ T cells. Responses to WT1 and PR1 but not BCR-ABL were detected in 10 of 18 healthy donors. Responses to WT1, PR1, or BCR-ABL were observed in 9 of 14 patients with CML before SCT and 5 of 6 after SCT, often to multiple epitopes. Responses were higher in patients with CML compared with healthy donors and highest after SCT. These antigen-specific CD8+ T cells comprised central memory (CD45RO+CD27+CD57-) and effector memory (CD45RO-CD27-CD57+) T cells. In conclusion, leukemia-reactive CD8+ T cells derive from memory T cells and occur at low frequencies in healthy individuals and at higher frequencies in patients with CML. The increased response in patients after SCT suggests a quantitative explanation for the greater effect of allogeneic SCT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829610     DOI: 10.1182/blood-2003-01-0150

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

Review 2.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

3.  Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.

Authors:  Qing Ma; Changqing Wang; Dan Jones; Kathryn E Quintanilla; Dan Li; Yang Wang; Eric D Wieder; Karen Clise-Dwyer; Gheath Alatrash; You Mj; Mark F Munsell; Sijie Lu; Muzaffar H Qazilbash; Jeffrey J Molldrem
Journal:  Cytotherapy       Date:  2010-08-24       Impact factor: 5.414

4.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 5.  T cell therapy in allogeneic stem cell transplantation.

Authors:  J H Frederik Falkenburg; Helen E Heslop; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

Review 6.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

7.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Authors:  Katayoun Rezvani; Agnes S M Yong; Stephan Mielke; Bipin N Savani; Laura Musse; Jeanine Superata; Behnam Jafarpour; Carol Boss; A John Barrett
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

8.  Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Authors:  Jeffrey K Davies; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

9.  Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Authors:  Gregory L Beatty; Jasmine S Smith; Ran Reshef; Kunal P Patel; Theresa A Colligon; Barbara A Vance; Noelle V Frey; F Brad Johnson; David L Porter; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-07-14       Impact factor: 12.531

10.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

Authors:  Katayoun Rezvani; Agnes S M Yong; Abdul Tawab; Behnam Jafarpour; Rhoda Eniafe; Stephan Mielke; Bipin N Savani; Keyvan Keyvanfar; Yixin Li; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.